Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
CrowdMedâs patented prediction market technology can uncover diagnoses to real-w...
CrowdMedâs patented prediction market technol...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...
TherapeuticsMD, Inc. is an innovative pharmaceu...
We are a fully integrated biopharmaceutical company focused on the development and...
We are a fully integrated biopharmaceutical com...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
Join the National Investor Network and get the latest information with your interests in mind.